The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Tissue function depends on cellular organization. While the properties of individual cells are
increasingly being deciphered using powerful single-cell sequencing technologies …

Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase
inhibitors (TKIs) such as imatinib have increased survival of chronic myeloid leukaemia …

The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from
chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Imatinib Mesylate (imatinib) was once hailed as the magic bullet for chronic myeloid
leukemia (CML) and remains a front-line therapy for CML to this day alongside other …

Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the
adult population. The course of CML is divided into three phases: the chronic phase, the …